Literature DB >> 2279380

The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients.

M A Pfaller1, I Cabezudo, R Hollis, B Huston, R P Wenzel.   

Abstract

The application of typing procedures for the purpose of strain differentiation among isolates of Candida albicans obtained from hospitalized patients has been limited. We have applied biotyping and DNA restriction fragment analysis (DNA fingerprinting) by using EcoRI to the study of C. albicans isolates obtained from hospitalized patients. A total of 68 isolates from 15 patients were studied. Thirteen subtypes were identified by biotyping, 8 by DNA fingerprinting, and 21 by a combination of the biotyping and DNA fingerprinting approaches (composite subtype). Both techniques were highly reproducible. In examining the strain variation among isolates obtained from multiple anatomic sites over time, we found that similar, if not identical, strains were recovered from the oropharynx, urine, stool, and blood in a given patient, and these strains persisted. Only rarely did two patients share the same composite subtype suggesting sporadic nosocomial transmission. The combination of biotyping and DNA fingerprinting improved strain discrimination compared to either method alone. Further investigation with these and other epidemiologic typing methods will be necessary to enhance the understanding of the epidemiology and pathogenesis of candidiasis in hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2279380     DOI: 10.1016/0732-8893(90)90080-f

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  16 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

Authors:  T V Krishnarao; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Molecular epidemiology of Candida albicans colonization and fungemia in very low birthweight infants.

Authors:  J L Robinson; A I Hartstein; R U Meuser; V H Morthland; M E Dragoon; W M Wenman
Journal:  Can J Infect Dis       Date:  1993-11

4.  Candida zeylanoides: another opportunistic yeast.

Authors:  D Levenson; M A Pfaller; M A Smith; R Hollis; T Gerarden; C B Tucci; H D Isenberg
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

5.  Restriction fragment analysis of a Candida tropicalis outbreak of sternal wound infections.

Authors:  B N Doebbeling; R J Hollis; H D Isenberg; R P Wenzel; M A Pfaller
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

6.  Molecular probe for typing strains of Candida albicans.

Authors:  P Postlethwait; B Bell; W T Oberle; P Sundstrom
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Genomic studies on killer yeasts belonging to the genus Pichia.

Authors:  G Morace; P Cattani; S Manzara; S Conti; M Gerloni; M Sanguinetti; B Posteraro; L Polonelli
Journal:  Antonie Van Leeuwenhoek       Date:  1992-10       Impact factor: 2.271

8.  Epidemiological analysis of Candida albicans strains by multilocus enzyme electrophoresis.

Authors:  D A Caugant; P Sandven
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  T Peng; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.